Biosimilars Benchmarking the key players With increasing regulatory clarity and high revenue potential interest in biosimilars increases

Introduction

With increasing regulatory clarity and the expiries of key patents covering innovator biologics, the development of biosimilars for a range of recombinant protein classes is becoming increasingly attractive. Although many companies are targeting the market, 12 companies dominate. These include established generics companies, leading biosimilars developers, plus emerging biosimilar developers.

Scope of this report

Overview of the biosimilars competitive landscape, examining how the key players dominate the environment

Update of in-depth profiles of the top-12 biosimilar developers

Identification of licensing and collaboration trends shaping the biosimilars environment

Analysis of biosimilar development trends in terms of target protein class, drug delivery and reformulation technology, and geographical launch market

Research and analysis highlights

Well-established generics companies such as Sandoz and Teva have led the drive into the biosimilars market, by launching across a range of emerging and Western markets in a small number of well-characterized and relatively simple recombinant protein classes with significant market potential.

Although established generics companies have so far dominated the biosimilars landscape, emerging biosimilar developers have the greatest number of disclosed pipeline biosimilar programs, which are set to broaden the range of biosimilars being developed in terms of protein class, drug delivery and formulation.

There has been significant licensing and M&A deal activity among the top-12 biosimilar companies, enabling them to build a stronger product portfolio and gain greater access to capabilities that are key to competing in this market, such as drug delivery (primarily advanced injection technology) and drug formulation (mainly pegylation) technologies.

Key reasons to read this report

Evaluate the competitive landscape of the top-12 biosimilar developers

Identify the trends shaping biosimilar product development among the top-12 biosimilar developers

Understand the drivers for licensing and M&A deals being conducted by the top-12 biosimilar developers.

Published: 20 December 2006

Format: PDF
Table of Contents
Price: $7,600.00 / GBP4,180.00